Patented Medicine Prices Review Board Schedules a Pre-Hearing Conference in the Matter of Alexion Pharmaceuticals Inc. and the Price of the Medicine Soliris

OTTAWA, ONTARIO--(Marketwired - June 18, 2015) - Patented Medicine Prices Review Board

The Patented Medicine Prices Review Board (PMPRB) will hold a public pre-hearing conference in the matter of the price of the patented medicine Soliris and Alexion Pharmaceuticals Inc., the pharmaceutical company that exercises patent rights for Soliris and sells the medicine in Canada. The pre-hearing conference will take place from 9:30 a.m. to 5:00 p.m. (EST) on Monday, June 22; Tuesday, June 23; and Wednesday, June 24, 2015 at the following location:

Patented Medicine Prices Review Board

Hearing Room #1

333 Laurier Avenue West, 18th floor

Ottawa, Ontario K1P 1C1

The purpose of the pre-hearing conference is to allow parties to identify or circumscribe the issues related to the hearing and resolve any other issues that may facilitate the conduct of the hearing.

Soliris is the first and only treatment for patients with Paroxysmal Nocturnal Hemoglobinuria-a rare and life-threatening blood disorder characterized by excessive destruction of red blood cells-and Atypical Hemolytic Uremic Syndrome, a rare and life-threatening genetic disorder characterized by blood clots in small vessels.

Quick Facts

• The Patented Medicine Prices Review Board is an independent quasi-judicial body that protects the interests of Canadian consumers by ensuring the prices of patented medicines sold in Canada are not excessive.
• Board Staff review the prices patentees charge for each individual patented drug product sold in Canadian markets on an ongoing basis.
• When Board Staff find the price of a patented drug appears not to comply with pricing guidelines, they will conduct an investigation to determine the facts. An investigation could result in: the closure of the file, where it is concluded that the price complies with pricing guidelines; a Voluntary Compliance Undertaking, whereby the patentee agrees to reduce the price and to offset excess revenues through a payment and/or additional price reductions; or a public hearing to determine whether the price is excessive.
• If the Board finds, as the result of a public hearing, that the price of a patented drug is excessive, the Board may order the patentee to reduce the price of the patented medicine and to offset any excess revenues it may have received.

Related Products

Notice of Hearing

Statement of Allegations of Board Staff

Additional Links

Status of Ongoing Proceedings (Patented Medicine Prices Review Board)

Compendium of Policies, Guidelines and Procedures (Patented Medicine Prices Review Board)